Genetic Screening in Korean Patients with Frontotemporal Dementia Syndrome

Patients

Patients were prospectively recruited from ten neurology clinics across Korea between June 2016 and January 2018. All patients that were enrolled in this study met the FTD criteria proposed by Knopman et al. [7] or the new consensus diagnostic criteria for bvFTD [8], svPPA, and nfvPPA [9]. Patients with clinical and electrophysiological evidence of ALS were enrolled as having FTD-ALS, regardless of the clinical subtype of FTD. This study was conducted as part of the Clinical Research Center for Dementia of South Korea–FTD (CREDOS-FTD) registry study, which was carried out between 2010 and 2018 [10]. All participants were registered in the CREDOS-FTD registry and evaluated using the CREDOS-FTD protocol. The protocol is composed of a clinical evaluation form (clinical history, neurological examination, Korean version of Mini-Mental State Examination, Hachinski ischemic scale, Global Deterioration Scale, Unified Parkinson’s Disease Rating Scale, and Frontotemporal-Clinical Dementia Rating sum of boxes score), caregiver questionnaire form (Korean dementia screening questionnaire, Barthel Activities of Daily Living, Seoul Instrumental Activities of Daily Living, and Caregiver-Administered Neuropsychiatric Inventory and Frontal Behavioral Inventory), and cognitive test battery for FTD, consisting of subdomains assessing attention, language, visuospatial, memory, and frontal/executive functions [10]. All patients underwent brain magnetic resonance imaging (MRI) to exclude any structural lesions. Patients with current or past neurological or psychiatric illnesses were excluded from this study.

The institutional review boards (IRB) at all participating centers approved the study (IRB No. 2012-12), and informed consent was obtained from each patient and caregiver. As informed consent did not include open access to the data used in the study, our data is not publicly available.

Genetic analysis

Genomic DNA was extracted from peripheral blood leukocytes using a standard procedure. WES was performed using an Agilent SureSelect All Exon kit 50 Mb (Agilent Technologies, Santa Clara, CA, USA) on a NextSeq 500 platform (Illumina Inc., San Diego, CA, USA). Alignment of sequence reads, indexing of the reference genome (GRCh37/hg19), and variant calling were performed using a pipeline based on GATK Best Practices. Variants with allele frequencies >0.001 were filtered out based on public databases, including the Genome Aggregation Database (http://gnomad.broadinstitute.org/) and 1,722 ethnically matched controls from the Korean Reference Genome Database (KRGDB) [11]. Thereafter, 32 genes related to ALS-FTD and 20 genes related to familial Alzheimer’s disease and other dementias that have been explored by the authors from OMIM (https://www.omim.org/), GeneReview (http://www.ncbi.nlm.nih.gov/books/NBK1116/), and high-quality published literature [1, 4] and introduced as causative genes of FTD-ALS spectrum disorders or dementia, were screened for pathogenic variants (Table 1). Missense, frameshift, indel, nonsense, synonymous, and intronic variants within the exon-flaking regions were also evaluated. Splice site and conservation analyses were performed for all synonymous variants using Human Splice Finder and GERP scores. All amino acid variants were confirmed using Sanger sequencing or DeepVariant (https://github.com/google/deepvariant, version 1.2.0). The variants were classified according to the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) guidelines [12]. The BP7 rule of the ACMG/AMP guidelines was only applied in cases that were being predicted as ‘no impact and not highly conserved’. Hexanucleotide repeat expansion of chromosome 9 open reading frame 72 (C9orf72) was tested for all patients using the triplet repeat-primed polymerase chain reaction, as previously described [13].

Demographic and clinical findings

A total of 72 patients (35 males and 37 females) with FTD were enrolled, including 38 with bvFTD, 26 with svPPA, six with nfvPPA, and two with FTD-ALS. One patient with FTD-ALS presented with abnormal behavior and the other presented with dysarthria followed by behavioral changes. The mean age was 65.8±10.3 years, and the mean age at disease onset was 63.9±11.5 years. The mean interval between disease onset and enrollment into the study was 3.6±2.3 years. Seventeen patients (23.6%) had a history of dementia or neuropsychiatric disease in a first-degree relative. The detailed demographic data is summarized in Table 2. During the preparation of this manuscript, a parallel study on telomere length in FTD syndrome was published by our group [14]. Of the 72 participants, 40 patients with sufficient DNA available for the Southern blotting analysis for telomere length after WES, were included in the parallel study.

Genetic findings

WES yielded an average read depth of 121.81x and the average for 10× coverage was 99.33%. After variant analysis, one likely pathogenic variant in the MAPT gene, c.2116G>A (p.G706R), was identified in a patient with bvFTD (FTD-18), which has been reported in familial or sporadic FTD [15]. FTD-18 had H1/H1 haplotypes of the MAPT gene and had been enrolled in an FTD modeling study using induced pluripotent stem cell (iPSC) technology and had been reported elsewhere [16]. The four variants of uncertain significance (VUSs) from ALS-FTD-related genes were also detected in four patients with FTD: PRNP gene, c.695T>G (p.M232R) in two patients with bvFTD (FTD-13, FTD-39), VCP gene, c.278G>T (p.R93L) in a patient with svPPA, and UBQLN2 gene, c.20G>A (p.S7N) in a patient with bvFTD (Table 3). Of these, p.M232R of the PRNP gene has been reported previously in Creutzfeldt–Jacob disease (CJD) [17], but its pathogenicity has been controversial. p.R93L of the VCP gene and p.S7N of the UBQLN2 gene were novel variants. None of the patients had abnormal repeat expansions of C9orf72. Regarding genes related to familial Alzheimer’s disease and other dementias, nine VUSs were identified from seven patients and one of them, p.L136S of the APP gene, was novel (Table 3).

Case carrying p.G706R in the MAPT gene

FTD-18 was a 32-year-old man with a three-year history of progressive behavioral changes and cognitive deficits. His symptoms included impatience, aggression, and emotional blunting. The patient became more inert and depressed with time. He also exhibited hypersexuality and an obsession with sweet foods and computer games. Episodic memory impairment, visuospatial dysfunction, language difficulties, and decline in personal hygiene and activities of daily living developed around the time of his first visit to the neurology clinic. His maternal grandfather had dementia at the age of 60. Neurological examinations were unremarkable. Neuropsychological evaluation revealed severely impaired memory, visuospatial, language, and executive functions. The MMSE score was 20 and the clinical dementia rating was 1. Brain MRI demonstrated bilateral and symmetric frontal atrophy (Fig. 1A). Florbetaben and flortaucipir PET revealed negative findings. The clinical syndromic diagnosis was bvFTD. His symptoms progressed rapidly, and two years after the initial evaluation, he was transferred to another hospital.

Fig. 1

A) Brain MRIs of FTD-18 who carried variant p.G706R of the MAPT gene, revealing bilateral and symmetric frontal atrophy. B) Brain MRIs and FDG-PET images of FTD-13 who carried variant M232R of the PRNP gene, showing cortical atrophy and severe glucose hypometabolism in the bifrontal areas. C) Brain MRIs of FTD-39 who carried variant M232R of the PRNP gene, demonstrating prominent bilateral frontotemporal atrophy, worse on the left.

Cases carrying p.M232R in the PRNP gene

FTD-13 was a 54-year-old man who worked as a construction manager. He was admitted to the psychiatric ward with rapidly progressive behavioral changes and memory impairment for six months. He repeatedly called friends to borrow money, although he was financially stable; he could not wait his turn at restaurants for food to be put on his plate; he obsessively called his son, until he convinced him to have lunch together; he woke his son up at 2 am to visit his parents’ grave and repeatedly asked the same questions. However, he was able to maintain normal daily living activities. Neurological examinations showed normal findings. The MMSE score was 26 and the global deterioration score (GDS) was 3. Neuropsychological test results showed impaired naming, memory, and frontal function. The patient had no family history of dementia. Initial brain MRI revealed prominent atrophy in bilateral frontal lobes. Diffusion-restricted areas were not detected on diffusion-weighted imaging (DWI). The follow-up MRIs, taken at one-month intervals, showed the same findings as the previous ones. Fluorodeoxyglucose-positron emission tomography (FDG-PET) demonstrated severe glucose hypometabolism in the bilateral frontal areas, which worsened on the right side (Fig. 1B). He was diagnosed with bvFTD and transferred to another hospital after six months of follow-ups.

FTD-39 was a 51-year-old man with a two-year history of behavioral changes. He was eating 15 meals per day due to increased appetite and gained 22 kg in a year; he went to the bathroom frequently, over 15 times a day; he provided short answers to questions and refused to take a bath; he showed poor spontaneity and sometimes talked to himself. Memory impairment, visuospatial dysfunction, language difficulties, and disorientation also developed in the patient. There was no family history of dementia. Neurological examinations did not reveal any significant changes. Initial MMSE score was 24, and the GDS was 4. However, brain MRI revealed bilateral frontotemporal atrophy, which worsened on the left side. Initially, he was diagnosed with schizophrenia in a psychiatric clinic and was referred to a neurology clinic where he was diagnosed with bvFTD. The 9-month follow-up MMSE score was 17, and the GDS was 5. Follow-up MRIs showed aggravated cortical atrophy in both frontal and temporal areas (Fig. 1C). After almost three years of follow-ups, the patient stopped visiting the hospital.

Cases carrying novel variants (p.R93L of the VCP gene, p.S7N of the UBQLN2 gene, and p.L136S of the APP gene)

FTD-36 with p.R93L of the VCP gene was a 50-year-old man, whose illness began at the age of 45; he presented memory impairment, followed by fluent aphasia, disinhibition, and myoclonic seizures. Brain MRI showed severe bi-frontotemporal atrophy, worse on the left side, and left parietal atrophy (Fig. 2A). Electroencephalography revealed partial seizures arising in both frontal areas. A clinical syndromic diagnosis of svPPA was made. His mother had a stroke. FTD-48 with p.S7N of the UBQLN2 gene was a 59-year-old woman, whose personality changes including apathy, indifference, loss of empathy, obsession, and disinhibition started at the age of 57. In contrast to the behavioral changes, her memory, language, and visuospatial functions were relatively preserved and her APOE genotype was ɛ3/ɛ4. Brain MRI revealed right asymmetric frontotemporal atrophy (Fig. 2B). The clinical syndromic diagnosis was bvFTD. The patient’s family history was unremarkable. This patient carried two more VUS: p.T421M of the PSEN2 gene and p.G638S of the GALC gene. The p.T421M of PSEN2 has been reported in an early onset sporadic AD patient, carrying APOE ɛ4/ɛ4, from Japan [18]. FTD-61 with p.L136S of the APP gene was a 66-year-old man whose illness began at the age of 58; he presented with apathy, disinhibition, and hyperorality, followed by right-side rigidity and gait disturbances at the age of 60. A brain MRI demonstrated prominent atrophy in the bifrontal and left temporal areas (Fig. 2C). A clinical syndromic diagnosis of bvFTD was made. Notably, his father had Parkinson’s disease.

Fig. 2

A) Brain MRIs of FTD-36 who carried variant p.R93L of the VCP gene, showing bi-frontotemporal atrophy (worse on the left) and left parietal atrophy. B) Brain MRIs of FTD-48 who carried variant p.S7N of the UBQLN2 gene, variant p.T421M of the PSEN2 gene and variant p.G638S of the GALC gene, revealing right asymmetric frontotemporal atrophy. C) Brain MRIs of FTD-61 who carried variant p.L136S of the APP gene, demonstrating prominent atrophy in the bifrontal and left temporal area.